PCS
MREO

Personal CFO Solutions’s Mereo BioPharma MREO Stock Holding History

Personal CFO Solutions’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-25,888
Closed -$29K – 475
2022
Q1 		$29K Hold
25,888
– – 0.01% 462
2021
Q4 		$41K Sell
25,888
-7,500
-22% -$15K 0.01% 467
2021
Q3 		$81K Hold
33,388
– – 0.02% 441
2021
Q2 		$106K Sell
33,388
-41,388
-55% -$139K 0.02% 422
2021
Q1 		$252K Buy
+74,776
New +$264K 0.05% 313

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Personal CFO Solutions's MREO Position: Q2 2022 in Review

Personal CFO Solutions sold out of Mereo BioPharma (MREO) in Q2 2022, closing a stake of 25,888 shares — an estimated $29K sold.

Personal CFO Solutions first reported a position in MREO in Q1 2021 and held it in 5 quarters. The position peaked at $252K in Q1 2021. 64 funds tracked by Wall St. Rank hold MREO as of Q2 2022.

  • Personal CFO Solutions reported no remaining Mereo BioPharma position as of Q2 2022 after selling out during the quarter.
  • Personal CFO Solutions sold 25,888 Mereo BioPharma shares in Q2 2022, an estimated $29K.
  • Personal CFO Solutions first reported a position in Mereo BioPharma in Q1 2021 and held it in 5 quarters.
  • Personal CFO Solutions's Mereo BioPharma position peaked at $252K in Q1 2021.
  • 64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2022.

Based on Personal CFO Solutions's 13F filing for Q2 2022, filed 5 Aug 2022.